Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

PARP inhibition and DNA Damage Response (DDR)

PARPi and DDR section Banner

The information on the site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

This site contains information and education for healthcare professionals.

This section has been developed as a resource providing information on PARP inhibition and DNA Damage Response (DDR) as therapeutic targets across multiple tumour types.

Information included in this website is compiled from review of the medical literature and expert guidance from Simon Boulton (The Francis Crick Institute, London; and Artios Pharma Ltd., Cambridge, UK), Judith Balmaña (Vall d’Hebron Institute of Oncology, and Vall d’Hebron University Hospital, Barcelona, Spain), Charlie Gourley (Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, UK) and Violeta Serra (Vall d’Hebron Institute of Oncology, Barcelona, Spain).

Find more about the learning objectives.

There are two modules. Click on the links below to find out more on PARP inhibition and the DNA Damage Response (DDR) pathway. We recommend that Module 1 is selected first, but the modules can be selected in any order.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings